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ABSTRACT 
 
Background: Obesity as a developing global challenge can be characterized by increase in adipocyte number and 
size arising from adipogenesis. Control of adipogenesis, as a potential strategy, can prevent and manage obesity. 
So far, the effectiveness of herbal medicine and active ingredients therapies for obesity and metabolic syndrome 
treatment has been investigated. In this study, a novel combination of berberine, catechin, and capsaicin was 
developed, and their effect on 3T3-L1 adipocytes was investigated. Methods: The effect of active ingredient on 
the cell viability was assessed by MTT assay. Adipocytes were treated with various concentrations of berberine (3 
and 6.25 μM), catechin (6.25 and 12.5 μM), and capsaicin (6.25 and 12.5 μM) alone and in combination. Results: 
All active ingredients did not affect the cell viability by MTT assay at different concentrations. The dual and triple 
combinations of three active ingredients showed excellent potential as anti-obese without any toxicity. The 
inhibitory effect of berberine, catechin, and capsaicin on the differentiation of 3T3-L1 preadipocytes was found to 
be dose-dependent. These results indicate that catechin in both doses may have a stronger effect than the  
two other active ingredients on the intracellular lipid accumulation. Also, the triple combination of  
the aforementioned ingredients showed better responses than their dual combination. Conclusion: This work is 
the first report to simultaneously investigate these three active ingredients in a single, dual, and triple formats. 
The berberine, catechin, and capsaicin co-treatment inhibits the adipogenesis during the differentiation process. 
This compound can be a prospective therapy for obesity and relevant diseases such as dyslipidemia.  
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INTRODUCTION 
 
besity is described as an extreme body fat 
accumulation, which is resulted from the 
imbalance between energy input and output
[1]
, 
and has a significant contribution to several chronic 
diseases, especially type 2 diabetes mellitus, 
cardiovascular diseases, sleep disorders,  dyslipidemia, 
osteoarthritis, and some sorts of cancers
[2-4]
. Obesity 
can be characterized by an increment in adipocyte 
number and size resulting from adipogenesis (the 
differentiation of preadipocytes toward mature 
adipocytes). Various contributing factors are found to 
have an influential impact on the hyperplasia (number) 
and hypertrophy (size) of adipocytes
[5]
. According to 
the World Health Organization, in 2016, over 1.9 
billion (39%) individuals aged 18 years and older were 
overweight, among which more than 650 million 
(13%) were considered as obese
[6]
. Obesity is mainly 
due to the accumulation of TG in adipocytes and an 
increase in their size. Control of adipogenesis as a 
possible approach can be useful to prevent and treat 
obesity, and the adipocyte differentiation is a major 
player in the adipose tissue growth
[7]
. 
So far, the effectiveness of hundreds of herbs and 
active ingredients has been investigated for the obesity 
and metabolic syndrome treatment. For instance, the 
active ingredient of berberine, found in the plants of 
Rhizoma coptidis and Cortex phellodendri, has 
traditionally been applied for the treatment of infection 
and diabetes
[8]
.  Some studies, have indicated that 
berberine, an isoquinoline alkaloid, can improve the 
metabolic syndrome and reduce plasma TG and 
cholesterol levels
[9, 10]
. Investigations on the impacts of 
berberine on obesity have revealed the adipogenesis 
inhibitory effects of this compound during the 
differentiating of 3T3-L1 preadipocytes
[7,8,11,12]
. A 
recent study has shown that this active ingredient can 
reduce the amount of TG accumulation through 
enhancing the expression of adipose TG lipase (Atgl) 
enzyme in 3T3-L1 adipocytes
[13]
. Berberine also 
increases the expression of brown adipose tissue 
marker and uncoupling protein 1, as well as promoting 
the differentiation of white into brown adipose tissues. 
Accordingly, berberine can strongly be helpful for 
thermogenesis and body weight loss
[10]
. 
Animal studies have demonstrated that the oral 
administration of green tea (Camellia sinensis) reduces 
the adipose tissue weight, and active ingredients in 
green tea, like catechin, may suppress adipocyte 
differentiation
[14]
. Another active ingredient for the 
treatment of obesity is capsaicin in placental tissue of 
red pepper. The consumption of this ingredient, which 
possesses an anti-adiposity property, has been 
associated with energy expenditure and reduced food 
intake
[15,16]
. 
The combination of some effective herbs and their 
active ingredients can increase their therapeutic effect. 
As an example, the compound Huanghousu 
synthesized from magnolol and berberine has been 
reported to improve lipid metabolism better than a 
single component
[17]
. Also, supplementation with 
catechin and resveratrol could enhance fat oxidation
[18]
. 
In this study, the design and effectiveness of a unique 
and an effectual composition, including berberine, 
catechin, and capsaicin, with potential use in treatment 
of obesity were studied.  
 
 
MATERIALS AND METHODS 
 
Materials and chemicals 
The 3T3-L1 cells were procured from the Iranian 
Biological Resource Center, Tehran, Iran. Berberine, 
capsaicin, and catechin (purity > 98%) were obtained 
from the Santa Cruz Biotechnology, USA. PBS, 
DMEM, and FBS were all purchased from Sigma-
Aldrich Company (GmbH Munich, Germany). INS, 
IBMX, and Oil Red O were acquired from Sigma 
Aldrich, USA, DEXA from Santa Cruz Biotechnology 
(CA, USA), ethanol and n-butanol from Merck 
Chemical Co. (Germany), and MTT from Sigma-
Aldrich (Germany). 
 
Viability of 3T3-L1 cells 
The effect of active ingredients on cell viability  was 
assessed by MTT assay. The 3T3-L1 cells were seeded 
onto 96-well plates at 1 × 10
4
 cells/well and maintained 
overnight. Cells were treated with different 
concentrations of berberine
[8]
, capsaicin
[19,20]
 (3, 6.25, 
12.5, 25, 50, and 100 μM) and catechin (6.25 , 12.5, 
25, 50, 100, and 200 μM)
[21]
 along with  the control  
for 24 hours. Subsequently, 50 μl of 5 mg/ml solution 
of MTT was added to each sample and incubated for 3 
hours (5% CO2 and 37 °C). In order to dissolve MTT 
formazan, DMSO was added. The absorbance was 
measured at 570 and 690 nm by ELISA microplate 
reader (Synergy, BioTek Instruments Inc., Germany).  
 
Cell culture and differentiation 
The 3T3-L1 preadipocytes were cultured in DMEM 
(10% FBS, 100 units/mL of penicillin, and 100 μg/mL 
of streptomycin in a humidified 5% CO2 incubator at 
37 °C for 10-12 days), while  refreshing  every  2 days. 
The 3T3-L1 preadipocytes were seeded on a six-well 
plate at a density of 2 × 10
5
 cells/well. Cells were 
grown in DMEM until a confluency of 70% for  
the  induction  of  adipose  differentiation  (day 0).  For 
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differentiation into mature adipocytes, cells were fed 
with a differentiation medium (by adding 0.25 μM of 
DEXA, 0.5 mM of IBMX, and 5 μg/mL of INS in 
DMEM containing 10% FBS) for two days (day 3). 
After that, the medium was refreshed, and the cells 
were stored in DMEM containing 10% FBS and 5 
μg/mL of INS, and the medium was refreshed on a 
two-day basis. On day 12, the differentiation of  3T3-
L1 into mature adipocytes occurred with an 
approximate rate of  90%
[22]
. During this time period, 
the 3T3-L1 cells were treated with active ingredients 
(berberine, catechin, and capsaicin alone or their 
combination) with different concentrations, and the 
effect of these treatments on lipid cumulation by 
adipocytes was examined by Oil Red O staining 
method (Fig. 1). Cells were treated with different 
concentrations of berberine (3 and 6.25 μM), catechin 
(6.25, and 12.5 μM), and capsaicin (6.25 and 12.5 μM). 
The negative and positive controls, in the present 
study, were preadipocytes treated with the similar 
amounts of DMSO.  
 
 
Measuring lipid accumulation by Oil Red O 
staining  
The differentiated adipocytes were rinsed twice with 
PBS, followed by 10% buffered formalin as a fixator at 
room temperature for 1 hour. After removing this 
solution, the cells were washed by distilled water and 
stained in a freshly diluted Oil Red O solution (0.3% 
Oil Red O solution, 60% isopropanol, and 40% water; 
Sigma-Aldrich, USA) at room temperature for 1 hour. 
Then  the cells were washed  twice with  distilled water 
and counterstained with hematoxylin for 10 seconds
[23]
. 
The cells were photographed and the lipid droplets 
were observed and counted by using an inverted 
microscope (TS100, Nikon, Tokyo, Japan). To 
quantify lipid accumulation, the Oil Red O stained-
cells were washed twice with 60% isopropanol and 
destained with isopropanol at 25 °C for 10 minutes. 
The absorbance of the extracted Oil Red O dye from 
the stained cells was then read at 540 nm by a 
microplate reader (Synergy, BioTek Instruments Inc., 
Germany). 
 
 
 
 
Fig. 1. The methodology of the experimental study. 
D
ow
nl
oa
de
d 
fro
m
 ib
j.p
as
teu
r.a
c.i
r a
t 2
2:3
4 I
RD
T o
n F
rid
ay
 Ju
ne
 19
th 
20
20
    
    
  [ 
DO
I: 1
0.2
92
52
/ib
j.2
4.3
.15
5 ]
  
Anti-Obesity Compound As a Lipid Accumulation Inhibitor Payab et al. 
 
 
158 Iran. Biomed. J. 24 (3): 155-163 
 
Statistical analysis  
Six repetitions of independent experiments were 
conducted. In the current study, the mean ± SEM was 
used to present the data. Also, one-way analysis of 
variance (ANOVA) and Tukey’s multi-comparison 
tests were conducted using StatsDirect (version 3.2.8), 
in order to define the statistical difference (p < 0.05) 
across the treated and control groups.  
 
Ethical statement 
The study was approved by the Ethics Committee of 
Endocrinology Metabolism Research Institute, Tehran 
University of Medical Sciences, Tehran, Iran (approval 
code: IR.TUMS.EMRI.REC.1395.0091). 
 
 
RESULTS 
 
Effects of berberine, catechin, and capsaicin on 
3T3-L1 preadipocyte cell viability 
In order to assess the effect of these compounds on 
viability of 3T3-L1 cells, the MTT assay was carried 
out. Accordingly, cells were treated with the various 
concentrations of berberine, capsaicin (3, 6.25, 12.5, 
25, 50, and 100 µM) and catechin (6.25, 12.5, 25, 50, 
100, and 200 µM). As shown in Figure 2, all active 
ingredients did not affect cell viability at different 
concentrations. The results indicated that berberine and 
capsaicin did not alter the cell viability at 
concentrations in the range of 3–100 µM (Fig. 2A and 
2C). Also, catechin had no effect on the cell viability at 
concentrations between 6.25 and 200 µM (Fig. 2B). 
Thus, we used the three compounds at various 
concentrations for subsequent experiments. Based on 
our findings, the non-cytotoxic concentrations of the 
mentioned compounds were selected to follow the 
inhibitory impacts of these compounds on lipid 
cumulating. 
 
Effect of berberine, catechin, and capsaicin on the 
lipid accumulation in 3T3-L1 adipocytes 
The 3T3-L1 preadipocytes were differentiated  
into mature adipocytes by 10 to 12 days. The  
anti-obesity potential of the three compounds was 
studied by determining pre-adipocyte differentiation 
into adipocytes. Oil Red O staining was applied  
to investigate the intracellular lipid cumulating in 3T3-
L1 preadipocytes. The inhibitory effects of berberine, 
catechin, and capsaicin on preadipocytes differentiation 
were dose-dependent. Also, for the combination 
phases, the concentrations of catechin (6.25 μM), 
capsaicin (12.5 μM), and berberine (3 μM and 6.25 
μM) were used. In microscopic examinations using Oil 
Red O staining, the number and the size of lipid 
droplets  in adipocytes were found  to  be  considerably 
less than the control group after treatment with  
the active ingredients (Fig. 3). Also, the quantitative 
measurements revealed that the intervention  
groups had less intracellular lipids accumulation. In the 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. The effects of berberine (A), catechin (B), and 
capsaicin (C) on the viability of 3T3-L1 cells. The cell viability 
of active ingredients was assessed by MTT assay. Cells were 
treated with various concentrations of berberine and capsaicin 
(3, 6.25, 12.5, 25, 50, and 100 µM), catechin (6.25, 12.5, 25, 50, 
100 and 200 µM) and control group for 24 hours. The 
absorbance was read at 570 nm by an ELISA microplate reader. 
Results are presented as the mean ± SEM (n = 6). *p ≤ 0.05, **p 
≤ 0.01, and ***p ≤ 0.001 are considered as a significant 
difference from the control group.   
 (A) 
(B) 
(C) 
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Fig. 3. Reduction in the lipid droplet accumulation in 3T3-L1 cells by berberine, catechin, and capsaicin co-treatment. 
Representative images were randomly selected, and sections of 3T3-L1 adipocytes were stained with Oil Red O treated with various 
concentrations of active ingredients alone and their combination. Scale bars = 20. 
 
 
 
quantitative measurements, after washing the Oil Red 
O stain, the results indicated that the intracellular 
accumulation of lipids in 3T3-L1 preadipocytes was 
notably lower than other groups and the group of 
control after treatment with catechin (Table 1).  
As shown in Table 1, among the active ingredients 
studied, catechin showed the highest efficacy in both 
doses of 6.25 and 12.5 μM; however, catechin caused 
the strongest inhibition of lipid accumulation among 
the compounds tested. The 12.5-μM catechin showed a 
remarkable reduction in the intracellular lipid 
accumulation in comparison with the other groups. The 
triple combination of berberine, capsaicin, and catechin 
indicated better responses than their dual combination, 
and the combination of 12.5 μM each of capsaicin and 
catechin was effective in a dual format. These results 
of our study indicate that triple combination may have 
a stronger effect than dual ones in case of inhibiting the 
adipocyte differentiation. 
 
 
DISCUSSION 
 
The adipogenesis and accumulation of lipids in 
adipocytes lead to obesity. Hence, reducing the amount 
of lipids stored in adipocytes is momentous for obesity 
preventing and treating. Several natural plant extracts 
and  their  active  ingredients are found to be influential 
in inhibiting adipogenesis
[24]
. Some of the latest 
investigations have indicated the anti-adipogenic  
roles of natural plants, including Coptidis rhizoma 
(berberine),   green   tea   (catechin),   and   red   pepper  
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   Table 1. Effects of active ingredients (berberine, catechin, and capsaicin alone and their combination) with 
different concentrations on the intracellular lipids accumulation in 3T3-L1 cells after Oil Red O staining 
Components Dose (μM) Mean (SD) p value 
Berberine 
3.00   107.89 ± 4.49 NS 
6.25 121.58 ± 6.1 ** 
 
   
Capsaicin 6.25 103.16 ± 5.15 ** 
12.5 113.68 ± 5.48 *** 
 
   
Catechin 
6.25   94.21 ± 4.51 *** 
12.5 80.00 ± 4.2 *** 
 
   
Berberine + capsaicin 
 
3.00 + 6.25 157.89 ± 7.50 *** 
6.25 + 12.5 103.16 ± 5.35 NS 
Berberine + catechin 
3.00 + 6.25 131.05 ± 6.2 * 
6.25 + 12.5 117.89 ± 6.1 NS 
 
   
Capsaicin + catechin 
6.25 + 6.25 127.89 ± 6.39 * 
12.5 + 12.5 114.74 ± 5.79 NS 
 
   
Berberine + capsaicin + catechin 
3.00 + 6.25 + 6.25 116.55 ± 5.62 * 
6.25 + 12.5 + 12.5 112.84 ± 5.14 * 
    
Con+ - 147.37 ± 7.36  
    
Con- -      100 ± 4.70 *** 
The negative (Con-) and positive (Con+) controls were preadipocytes treated with 0.1% DMSO. Results are 
presented as the mean ± SD from three independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001 compared 
with the control group). NS, not significant  
 
 
(capsaicin), which have anti-obesity properties
[8,15,21]
. 
The purpose of the present study was to assess the anti-
adipogenic properties of berberine, catechin, capsaicin 
during single or multiple treatments. Our findings 
indicated that these compounds alone or in dual  
and triple  combinations  decreased the lipid  content in 
adipocytes, and that these active ingredients may have 
possible application as an anti-obesity impact. The 
results of the cell viability assays indicated that the 
reduced accumulation of lipid in 3T3-L1 adipocytes 
treated with the active ingredients was not due to their 
toxicity but because of antilipogenic properties. 
In vitro and in vivo investigations have shown that 
the intracellular lipid accumulation and adipocyte size 
decrease after treatment with berberine in a dose-
dependent manner
[8,10,25]
. Moreover, our research has 
confirmed that berberine in doses of 3 μM and 6.25 μM 
reduced the lipid accumulation both in size and in 
number. Studies have pinpointed that berberine can 
inhibit adipocyte differentiation through various 
mechanisms
[26,27]
. Berberine plays a role in the up-
regulation of genes involved in energy expenditure and 
down-regulation of genes involved in adipogenesis
[12]
. 
Berberine decreases the expressions of peroxisome 
PPARγ, C/EBPα, where they act as key transcription 
factors at the initial steps of differentiation as well as 
other adipogenic genes like SREBP-1c, Scd1, FASN, 
and ACC
[13,26,28]
. Also, berberine up-regulates the 
expression of Atg1
[13]
.  
Another effective active ingredient in the 
adipogenesis inhibition, investigated in the present 
research, was capsaicin, which was used at the doses of 
6.25 μM and 12.5 μM. Previous studies have revealed 
that capsaicin inhibits the adipocyte differentiation and 
intracellular lipid accumulation
[29,30]
.  Findings from a 
study revealed that capsaicin plays a dual role in 
inhibiting adipogenesis, activating transient receptor 
potential cation channel subfamily V member 1, and 
inducing brown-like phenotype at higher doses in 3T3-
L1 adipocytes. The anti-adipogenic effects of capsaicin 
are associated with brown-like phenotype
[31]
. 
Additionally, capsaicin decreases the PPARγ, C/EBPα, 
and leptin expression and increases the lipoprotein 
lipase expression, indicating the ability of capsaicin to 
inhibit the 3T3-L1 preadipocytes differentiation
[29]
. 
Besides energy efficiency and feeding control,  
some other strategies, including increasing energy 
expenditure, controlling fat, and carbohydrate 
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absorption, as well as proliferation and  differentiation 
inhibiting  of preadipocytes have been introduced  
for the obesity treatment
[32]
. In the present study,  
doses of 6.25 μM and 12.5 μM were used for catechin, 
which has many inhibitory effects on obesity.  
Catechin decreases PPARγ and C/EBPα (key 
transcription factors of the initial stage of transcription) 
expression, thus inhibiting the differentiation of fat 
cells
[21]
. 
PGC-1α has a key function in the carbohydrate, 
lipid, and energy homeostasis. As an energy regulator, 
PGC-1α accelerates the oxidation of the fatty acids by 
enhancing the function and activity of mitochondria, 
which has an effect on the body's energy 
expenditure
[33,34]
. The overexpression of  PGC-1α gene 
is performed by catechin through the promoter 
activation
[35]
.Some studies have also pointed out that 
catechin has an impact on  fatty acids oxidation and 
energy expenditure by the genes expression regulation 
in adipose tissue, including the expression of hormone-
sensitive lipase and UCP1 gene
[36]
. 
So far, no study has been conducted to examine the 
simultaneous effects of these three active components 
for the inhibition of adipogenesis.  In one study, the 
inhibitory effects of capsaicin and catechin on 
adipocytes differentiation was investigated and  
these two compound showed to inhibit adipogenic 
activity via promoting Adenosine monophosphate-
activated kinase, one of the primary targets for the 
inhibition of adipocyte differentiation and controlling 
adipogenesis
[30]
. 
According to the results of the present study, the dual 
and triple combinations of berberine, catechin, and 
capsaicin have excellent potential as effective anti-
obesity agents without any toxicity. The co-treatment 
of the mentioned compounds inhibited the 
adipogenesis during the differentiation process. This 
compound can be a potential therapy for obesity and 
relevant diseases such as dyslipidemia. Considering the 
effectiveness of the aforementioned active ingredients, 
the present study paves the way for future animal and 
human studies. More researches are required to explore 
the molecular mechanisms of these active ingredients. 
One of the strengths of this study is that the active 
ingredients (berberine, catechin, and capsaicin) that 
examined by various mechanisms have the ability to 
inhibit the intracellular lipid accumulation. 
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